|
Fig. 5
Inhibition of RA restores the sizes of the cardiovascular progenitor fields in Cyp26-deficient embryos. (A-D) nkx2.5 expression in wild-type, DEAB-treated, Cyp26-deficient and Cyp26-deficient+DEAB-treated embryos. (C) Cyp26-deficient embryos have an anterior shift in nkx2.5 expression, which is rescued in (D) DEAB-treated Cyp26-deficient embryos and comparable with wild-type and DEAB-treated embryos (A,B). Arrows in A-D indicate distances between posterior eye and the anterior border of nkx2.5 expression. (E-H) etv2 expression in wild-type, DEAB-treated, Cyp26-deficient and Cyp26-deficient+DEAB-treated embryos. (G) Cyp26-deficient embryos show a posterior truncation in etv2 expression, which is rescued in DEAB-treated Cyp26-deficient embryos (H). (I) Measurements of length of etv2 expression and distance from the anterior tip of the embryo to anterior border of nkx2.5 expression. For etv2 measurements: WT, n=27; DEAB-treated, n=30; Cyp26-deficient, n=17; Cyp26-deficient + DEAB-treated embryos, n=22. For nkx2.5 measurements: WT, n=27; DEAB-treated, n=26; Cyp26-deficient, n=18; Cyp26-deficient + DEAB-treated embryos, n=22. All images are dorsal views with anterior upwards. Significant differences compared with controls are indicated (*P<0.05). Error bars indicate s.d.